Compare ClearPoint Neuro Inc (CLPT) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Okta, Inc. — how do they compare? ClearPoint Neuro Inc trades at $15.86 (market cap $478.63M), while Okta, Inc. trades at $150.24 (market cap $26.87B). The key difference: Okta, Inc. is far larger — about 56.1× ClearPoint Neuro Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | OKTA | |
|---|---|---|
Market Cap | $478.63M | $26.87B |
Sector | Health | Technology |
52-Week High | $29.60 | $154.62 |
52-Week Low | $8.66 | $62.93 |
Enterprise Value | $506.63M | $24.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
OKTA trades at $139.53, up 0.65% today, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.91 exceeding the $0.853 estimate. Revenue grew to $2.61 billion in 2025, and net income turned positive at $28 million. Analyst sentiment is positive, with 72.55% recommending Buy.
The outlook is favorable due to AI-driven demand for cybersecurity, but high valuation multiples pose risks. The stock faces competition and must sustain growth to justify its P/E of 101.11. Upside exists if earnings continue to beat expectations, yet volatility from market sentiment shifts is a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
